Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock, while a blockbuster approval can generate spectacular returns. For many investors, this extreme volatility is a deterrent. However, an alternative model exists that allows participation in the industry’s upside while mitigating its most significant risks.
Royalty Pharma plc (NASDAQ: RPRX) has mastered this approach. Operating as a strategic financier rather than a traditional drug developer, the company has rewarded investors with a year-to-date stock appreciation of over 42%.
